1:1 Midnight Topical 150mg

by Tikun Olam
HybridTHC 7%CBD 10%
Strain rating:

About this product

Midnight, named after the midnight hour (12+12 = 24, the midnight hour), Midnight comes on delicately with an uplifting sensation that’s calming and euphoric. The balanced 1-to-1 ratio of THC to CBD makes it a go-to strain for clear-headed pain relief and daytime focus.

Our all-natural topicals have a rich body butter texture. With a base of mango and shea butter, our topicals provide a silky texture and terpene enhanced to provide full-spectrum benefits. With a mango and shea butter base, our terpene enhanced topicals provide full-spectrum benefits in a silky, smooth texture. Tikun topicals go on effortlessly and stay on for extended relief. We use the same cannabis extract that is used in our vapes and tinctures to ensure delivery of the full cannabinoid spectrum.

About this strain

Midnight, a popular strain in Israel, is a sativa-dominant variety developed by Tikun Olam to treat nausea. This high-CBD strain also controls pain, inflammation, and indigestion, with uplifting and invigorating effects ideal for daytime consumption.

Something not right? Suggest an edit
No product reviews
Have you tried this product? Be the first to leave a review!

About this brand

Logo for the brand Tikun Olam
Tikun Olam
Shop products
Tikun Olam, meaning “Repair the World” in Hebrew, became the world’s first organization licensed by a national government to treat patients with medical cannabis. Since 2009, Tikun Olam has curated and produced specific cannabis-based therapies, evaluated individual patient conditions, recorded treatment outcomes, conducted with leading Israeli medical institutions safety and efficacy trials on the medicines derived from its unique strains, and published and presented over twenty peer-reviewed white papers. Extending Tikun Olam’s mission to the United States, its American affiliate leverages this extensive track record of learning and practical experience, offering consistently high-quality products targeting symptomatic relief.

License(s)

  • US: C11-0000181-LIC
Notice a problem?Report this item